We collaborate with Sage Therapeutics, a neuroscience-product-focused company creating novel medicines to treat important central nervous system disorders, to get new neurosteroid drugs into clinical trials as quickly as possible.
The goal of the collaboration is to significantly cut the lag time between laboratory discoveries and studies involving human patients.
Sage Therapeutics, a Boston, Mass., start-up company developed under the leadership of Steven Paul, MD, is focused on developing neuroactive steroids for use in anesthesia and in the treatment of neuropsychiatric disorders. The company recently announced the first effective use of a neuroactive steroid to treat a rare form of epilepsy called status epilepticus and is working on other applications.
In collaboration with Washington University School of Medicine and Weill Cornell Medical College, the company has also been involved in the discovery of a potential drug target for schizophrenia and other mental illnesses. The target molecule, known as an oxysterol, can stimulate receptors on brain cells important in cognitive function. This finding could lead to the development of new types of antipsychotic drugs.
Several members of the Institute are actively engaged with Sage Therapeutics in its mission. Douglas Covey, PhD, is a founding member based upon his expertise in the chemical synthesis of novel neurosteroid analogues. These novel analogues build upon the steroid structural platform and have strong potential for development as therapeutic agents in a variety of psychiatric and neurological illnesses.
Charles Zorumski, MD, serves on Sage’s Scientific Advisory Board and Alex Evers, MD, is a consultant.